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Azole resistance is an emerging problem in Aspergillus fumigatuswhich translates into treatment failure. Alternative treatments
with new azoles may improve therapeutic outcome in invasive aspergillosis (IA) even for strains with decreased susceptibility to
current azoles. The in vivo efficacy of 0.25, 1, 4, 16, 64, 128, 256, and 512 mg/kg of body weight/day prodrug isavuconazonium
sulfate (BAL8557) (isavuconazole [ISA]-equivalent doses of 0.12, 0.48, 1.92, 7.68, 30.7, 61.4, 122.9, and 245.8 mg/kg/day, respec-
tively) administered by oral gavage was assessed in an immunocompetent murine model of IA against four clinical A. fumigatus
isolates: a wild-type isolate (ISAMICEUCAST, 0.5 mg/liter) and three azole-resistant isolates harboring substitutions in the cyp51A
gene: G54W (ISAMICEUCAST, 0.5 mg/liter), M220I (ISAMICEUCAST, 4 mg/liter), and TR34/L98H (ISAMICEUCAST, 8 mg/liter). The
maximum effect (100% survival) was reached at a prodrug isavuconazonium sulfate dose of 64 mg/kg for the wild-type isolate,
128 mg/kg for the G54Wmutant, and 256 mg/kg two times per day (q12) for the M220I mutant. A maximum response was not
achieved with the TR34/L98H isolates with the highest dose of prodrug isavuconazonium sulfate (256 mg/kg q12). For a survival
rate of 50%, the effective AUC0–24/MICEUCAST ratio for ISA total drug was 24.73 (95% confidence interval, 22.50 to 27.18). The
efficacy of isavuconazole depended on both the drug exposure and the isavuconazole MIC of the isolates. The quantitative rela-
tionship between exposure and effect (AUC0–24/MIC) can be used to optimize the treatment of human infections by A. fumiga-
tus, including strains with decreased susceptibility.
Invasive aspergillosis (IA) caused by Aspergillus fumigatus is animportant opportunistic fungal infection in immunocompro-
mised patients with an overall mortality ranging between 30 and
88% (1–4). Azole antifungals, such as voriconazole (VRC) and
posaconazole (POS), are recommended drugs to manage Asper-
gillus diseases (5, 6). Voriconazole is currently recommended as a
first-choice treatment for IA, and posaconazole is indicated for
prophylaxis and salvage therapy (5, 6). However, the management
of IA has become more complicated due to the emergence of azole
resistance in A. fumigatus (7–16). Surveillance studies indicate
that azole resistance is increasing in multiple European countries
and in the Middle East, Asia, and Africa (17–21). Therefore, alter-
native treatment regimens need to be investigated to improve the
outcome of patients with azole-resistant IA.
There are basically two alternative options with respect to
the management of azole-resistant IA: treatment with a new
antifungal formulation or combination therapy. Recent data
suggest that combination therapy using a triazole and an echi-
nocandin may be a beneficial treatment strategy for triazole-
resistant isolates (22–24). However, for voriconazole, both in
vitro interactions and in vivo studies indicated that the level of
synergistic effect is lost at high voriconazole MICs (MIC of8
mg/liter) (22, 23). As a consequence, this is a major drawback
in the treatment of patients with azole-resistant IA. Therefore,
it is important to explore the efficacy of new antifungal drugs
against azole-resistant IA.
Isavuconazole (ISA) is an investigational broad-spectrum tri-
azole currently being investigated in phase III clinical studies for
the treatment of severe invasive fungal infections, including the
SECURE (invasive aspergillosis and other filamentous fungi),
VITAL (rare fungi), and ACTIVE (candidemia/invasive candidi-
asis) programs (http://clinicaltrials.gov). Isavuconazole is admin-
istered as a water-soluble prodrug, isavuconazonium sulfate, that
is available in both intravenous (i.v.) and oral formulations. The
prodrug is rapidly converted to the active moiety, isavuconazole,
and nonactive metabolite upon administration. It is now granted
Food and Drug Administration (FDA) fast-track status in the
United States and received “orphan drug” designation in the
United States and European Union for the treatment of invasive
aspergillosis and mucormycosis (25). FDA also recently desig-
nated isavuconazole as a Qualified Infectious Disease Product
(QIDP) for the oral and intravenous treatment of invasive asper-
gillosis, invasive mucormycosis, and invasive candidiasis (news
release, 16 July 2014, Basilea, Basel, Switzerland). In Europe, an
application also has recently been submitted to the European
Medicines Agency (EMA), seeking approval for isavuconazole to
be used for the treatment of invasive mold infections (news re-
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lease, 17 July 2014, Basilea, Basel, Switzerland), on the basis of the
SECURE registration study (26).
There are only limited preclinical data on the in vivo efficacy of
isavuconazole in azole-resistant IA (27). Therefore, the objective
of the present study was to investigate the pharmacodynamics
(PD) and dose-response and exposure-response relationships of
isavuconazole against wild-type and clinical azole-resistant A. fu-
migatus isolates harboring different substitutions in the Cyp51A
gene in an immunocompetent murine model of disseminated
aspergillosis. Survival and reduction in kidney fungal burden de-
termined by real-time quantitative PCR were used as primary and
secondary endpoints (respectively) to determine the dose-effect
and the exposure-effect relationships of isavuconazole for suscep-
tible as well as azole-resistant isolates in comparison with the
other azoles.
(Parts of these results were presented at the 53rd Interscience
Conference on Antimicrobial Agents and Chemotherapy, Denver,
CO, 10 to 13 September 2013, and at the 24th European Congress
of Clinical Microbiology and Infectious Diseases [ECCMID], Bar-
celona, Spain, 10 to 13 May 2014.)
MATERIALS AND METHODS
Fungal isolates. Four clinical A. fumigatus isolates obtained from patients
with proven IA (classified according to European Organization for Re-
search and Treatment of Cancer/Invasive Fungal Infections Cooperative
Group and National Institute of Allergy and Infectious Diseases Mycoses
Study Group [EORTC/MSG] consensus definitions) (28) were used in the
experiments: a wild-type isolate without mutations in the cyp51A gene
(AZN8196) and three azole-resistant isolates harboring substitutions in
the cyp51A gene: G54W (V 59-73) and M220I (V 28-77) isolates that have
become resistant during patient azole therapy and a TR34/L98H (V 52-35)
isolate that has become resistant through environmental azole exposure.
Strain identification and the cyp51A gene substitutions were confirmed by
sequence-based analysis as described previously (9). In addition, micro-
satellite genotyping of the isolates was performed to confirm that they are
genetically distinct (29). The isolates were stored in 10% glycerol broth at
80°C and were cultured on Sabouraud dextrose agar (SDA) supple-
mented with 0.02% chloramphenicol for 5 to 7 days at 35 to 37°C. All
isolates were cultured again on SDA for 5 to 7 days at 35 to 37°C before
preparation of the inoculum.
Preparation of inoculum for antifungal susceptibility testing. The
suspensions of conidia were harvested in normal saline containing
0.025% Tween 20. The appropriate dilutions in normal saline were made
to obtain a final inoculum concentration of 2  105 to 5  105 CFU/ml
(30).
In vitro antifungal susceptibility testing. In vitro antifungal suscep-
tibility testing (MICs and minimum effective concentrations [MECs])
was performed by using the EUCAST (European Committee for Antimi-
crobial Susceptibility Testing) (30) and CLSI (Clinical and Laboratory
Standards Institute) (31) broth microdilution guidelines. The final con-
centrations of the antifungal agents ranged from 0.016 to 16 mg/liter for
amphotericin B (AmB), itraconazole (ITC), voriconazole (VRC), po-
saconazole (POS), isavuconazole (ISA), and anidulafungin (AFG). Ali-
quots of 100l of each drug at a concentration two times the targeted final
concentration were dispensed in microtiter plates (Costar, Corning, NY).
Trays were maintained for a period of less than 1 month at 70°C until
the day of testing. After the microtitration trays were defrosted, 100 l of
the inoculum was added to each well, corresponding to a final concentra-
tion of 2 105 to 5 105 CFU/ml for each isolate. The microtiter plates
were incubated at 35 to 37°C for 48 h.
Growth inhibition was quantified by using a visual mirror. Candida
parapsilosis (ATCC 22019) and Candida krusei (ATCC 6258) were used
for quality control (QC) in all experiments. All incubations were per-
formed in three independent replicates, and the breakpoints reported by
Verweij et al., have been used for classifying azole-susceptible and azole-
resistant isolates (32).
The MIC was defined as the lowest concentration that completely
inhibited growth in comparison to the drug-free well (control) as assessed
by visual inspection. The MEC was defined as the lowest concentration in
which abnormal, short, and branched hyphal clusters were observed in
contrast to the long, unbranched hyphal elements that were seen in the
growth control well (30).
Antifungal agents. Isavuconazole (BAL4815) and the prodrug isavu-
conazonium sulfate (BAL8557) were provided by Astellas Pharma B.V.
For in vitro studies, isavuconazole was dissolved in dimethyl sulfoxide
(DMSO) prior to susceptibility testing. The concentration of DMSO in
the culture medium tubes was adjusted at 1%, and the concentration of
antifungal agents was 2 final concentration.
For in vivo studies, the prodrug was dissolved in sterile water prior to
oral administration in each experiment. Amounts of prodrug dissolved
were corrected for its 89% purity. The conversion factor for determining
the equivalent isavuconazole active dose from the prodrug dose was 0.48
(provided by Astellas Pharma B.V.) on a milligram-per-kilogram-of-
body-weight basis. Thus, for every 1 mg/kg of prodrug administered
orally, the equivalent in vivo isavuconazole dose was considered 0.48 mg/
kg. In the pharmacokinetic study, only isavuconazole (active drug
BAL4815) concentrations were quantified. The purity of isavuconazole
powder (BAL4815) for in vitro susceptibility testing was99%.
Infection model. The efficacy of isavuconazole monotherapy was de-
termined in an immunocompetent mouse model of disseminated asper-
gillosis following intravenous inoculation. Animals were infected via in-
jection of 0.1 ml of the conidial suspension into the lateral tail of the
mouse, corresponding to the 90% lethal dose (LD90) for each isolate (23,
33, 34). A total of 756 outbred CD-1 (Charles River, the Netherlands)
female mice, 4 to 5 weeks old, weighing 20 to 25 g, were randomized into
groups of 14 mice (11 for survival analysis; 3 for quantitative real-time
PCR [qPCR]) to control or prodrug doses.
Before performing the experiment, the isolates were cultured once on
SDA for 5 days at 35 to 37°C and subcultured twice on 15-cm Takashio
slants for 5 days at 35 to 37°C. The conidia were harvested in 20 ml of
sterile phosphate-buffered saline (PBS) plus 0.1% Tween 80 (Boom B.V.
Meppel, the Netherlands). The conidial suspension was filtered through
sterile gauze folded four times to remove any hyphae, and the number of
conidia was counted in a hemocytometer. After the inoculum was ad-
justed to the required concentration, the conidial suspension was stored
overnight at 4°C. The 90% lethal dose (LD90) was determined for each
isolate, separately. The LD90 was 2.4  10
7 (wild-type control), 1  107
(G54W strain), 5 107 (M220I strain), and 2.5 107 (TR34/L98H strain)
conidia. Confirmatory postinfection viability counts of the injected inoc-
ula were determined to ensure that the correct inoculum had been in-
jected.
Treatment was started 24 h after infection and continued for 14 days.
The prodrug solution was administered in doses of 0.25, 1, 4, 16, 64, 128,
and 256 mg/kg by oral gavage once daily in a volume of 0.12 ml or divided
into two or three daily doses where applicable. The highest dose (256
mg/kg) was used two times per day, corresponding to 512-mg/kg prodrug
isavuconazonium sulfate (BAL8557)/day in groups of animals where
100% efficacy was not achieved with a once-daily dose. The above-men-
tioned dosages were equivalent to 0.12, 0.48, 1.92, 7.68, 30.7, 61.4, and
122.9 mg/kg, respectively, of the active moiety isavuconazole. The control
group received single doses of saline. In addition, dose fractionation stud-
ies were performed to determine which pharmacokinetic/pharmacody-
namic (PK/PD) index correlated with efficacy. Mice were infected with
the A. fumigatus isolate through the lateral tail vein, and after 24 h, treat-
ment was initiated according to total daily dosing every 8 h (q8) or 12 h
(q12) for 14 days. The animals were housed under standard conditions,
with drink and feed supplied ad libitum. The animal studies were con-
ducted in accordance with the recommendations of the European Com-
munity (Directive 2010/63/EU revising Directive 86/609/EEC on the pro-
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tection of animals used for scientific purposes adopted on 22 September
2010), and all animal procedures were approved by the Animal Welfare
Committee of Radboud University (RU-DEC 2012-050).
In all survival studies, the monitoring was performed by experienced
individuals blinded to the animal treatment. The infected mice were ex-
amined at least three times daily. Clinical inspections focused on dehy-
dration, torticollis, staggering, severe weight loss (a decrease of 15%
within 48 h or 20% within 24 h), or body temperature drop to below 33°C.
Mice demonstrating these clinical signs were humanely terminated ac-
cording to strict protocols. On day 15 postinfection, all surviving mice
were humanely euthanized under isoflurane anesthesia, and blood and
internal organs were collected.
Survival and reduction in fungal burden were the primary end-
point in groups of 11 and 3 mice, respectively. The survival in days
postinfection was recorded for each mouse in each group and consid-
ered primary outcome-effect measure to assess the therapeutic efficacy
of isavuconazole (35). On day 3 postchallenge, a quantitative real-time
PCR (qPCR) was performed in groups of 3 mice. In these groups, the
mice were sacrificed on day 3 postinfection (before they began to die
from infection) and the fungal load in the kidney was determined. In
the systemic aspergillosis model with i.v. infection, the kidneys are the
main target organs, which may that indicate intraluminal localization
of the fungus in the renal tubules initially protects them from inflam-
matory cells. The reduction in kidney fungal burden was then corre-
lated with the survival of the remaining 11 mice from each correspond-
ing group at day 15 postinfection.
Determination of fungal burden in kidney. Left and right kidneys
from each animal were homogenized using a TissueLyser (Qiagen; Tis-
sueLyser Type MM 301) and UV irradiated beads with magnetic metal
cores (3 mm) and 30 Hz in 2 min. Tissue samples were transferred to
MagNA Lyser Green bead tubes (Roche Applied Science). Five hundred
microliters of Tris-EDTA (TE) buffer was added, and homogenization
was performed for 20 s at 6,500 rpm by using the MagNA Lyser instru-
ment. Supernatant was used for DNA isolation by using the automated
MagNA Pure (MP96) system and the MagNA Pure LC total nucleic acid
isolation kit according to the manufacturer’s protocol (Roche Applied
Science). Phocine herpesvirus (PhHV) was added to all samples as an
internal extraction and inhibition control. The concentration of total iso-
lated DNA was measured by using the NanoDrop ND-1000 spectropho-
tometer (Thermo Scientific). Aspergillus loads were determined by qPCR
using the LC480 instrument and the probe master kit (Roche Applied
Science), as previously described (36). Briefly, thermocycling conditions
were 95°C for 5 s, 50 cycles of 95°C for 15 s and 60°C for 45 s, and finally
40°C for 30 s, one time. The multicopy 28S rRNA gene of Aspergillus sp.
was detected by using primers F 5=-TCCTGCTCCTTAGTAGCCTGGT
T-3= and R 5=-GTGCTCCTTGCTTCACCTG-3= and probe 6-carboxy-
fluorescein (FAM)–AGTGACAGCCCTCAGCGACGAA-BBQ. Addi-
tionally, the PhHV isolation control was detected by using primers F 5=
TCCTGCTCCTTAGTAGCCTGGTT-3= and R 5=-GTGCTCCTTGCTTC
ACCTG-3= and probe FAM-AGTGACAGCCCTCAGCGACGAA-BBQ
(BlackBerry quencher). For the 28S rRNA detection, an 8-fold dilution
series of the cloned PCR product was included to calculate the number of
copies per milliliter. The ratio of copies per milliliter and total DNA iso-
lated (nanograms per milliliter) was calculated to determine the Aspergil-
lus load of each organ sample.
Pharmacokinetic analysis of isavuconazole in mice. A total of 210
outbred CD-1 (Charles River, the Netherlands) female mice, 4 to 5 weeks
old, weighing 20 to 22 g, were used for the PK experiments. On day 0, mice
were infected with the wild-type A. fumigatus isolate through the lateral
tail vein, and after 24 h, treatment with the prodrug isavuconazonium
sulfate was initiated at dosages of 0.25, 1, 4, 16, 64, 128, and 256 mg/kg of
body weight by oral gavage (ISA-equivalent doses of 0.12, 0.48, 1.92, 7.68,
30.7, 61.4, 122.9, and 245.8 mg/kg/day, respectively). At day 2 of treat-
ment (day 3 after infection), blood and bronchoalveolar lavage (BAL)
fluid samples were drawn from 3 mice for each individual predefined
sampling time point (10 time points in total): immediately before admin-
istration of drugs (0.0 h) and subsequently at 0.25, 0.5, 1, 2, 4, 8, 12, 24, and
48 h postdose. The blood samples were drawn through the orbital vein or
heart puncture into lithium-heparin-containing tubes and were cooled
and centrifuged for approximately 10 min at 1,000 g within 30 min of
collection. Plasma was aspirated, transferred in two 2-ml plastic tubes,
and stored at80°C. BAL fluid samples were obtained using a technique
described previously (37). After being sacrificed under isoflurane anesthe-
sia followed by cervical dislocation, the mice were secured on a plastic
platform. The trachea was exposed by a 1-cm incision on the ventral neck
skin for insertion of the cannula and sutured in place. Lungs were instilled
4 times with 0.5 ml of sterile 0.9% saline, with the fluid being immediately
aspirated. The aspirates recovered from the instillations were pooled per
mouse, placed on ice after each aliquot, and subsequently stored at
80°C.
Analytical assay of isavuconazole. Isavuconazole (BAL4815) concen-
tration in plasma and BAL fluid was measured by a validated ultraperfor-
mance liquid chromatography (UPLC) method with fluorescence detec-
tion. Details of the analytical assay are described elsewhere (38). Briefly,
samples were pretreated using a protein precipitation procedure (aceto-
nitrile-methanol, 50/50, and formic acid, 0.1%). A seven-point calibra-
tion curve with three quality control (QC) samples was used. All measure-
ments were done in duplicate. The dynamic range of the isavuconazole
assay was 0.0495 to 29.69 mg/liter, and the accuracy range, which was
dependent on the concentration, was 96.1% to 101.5%. Interday coeffi-
cient of variation was 0.46 to 1.8%, and extraction recovery was 84.6%.
The assay was validated for the mouse plasma matrix according to the
FDA and EMA directive for bioanalytical methods validation with the
exception of intraday precision as well as freeze-thaw cycles. These exper-
iments were not considered necessary based on the experience with hu-
man plasma.
Pharmacokinetic analysis. Geometric mean concentrations of isavu-
conazole were calculated for each time point (n 3 mice). Pharmacoki-
netic parameters (area under the concentration-time curve from 0 to 24 h
[AUC0 –24], maximum concentration of drug in serum [Cmax], the trough
concentration 24 h after the start of treatment [C24 h], half-life [t1/2],
volume of distribution [V], clearance [CL], and terminal elimination rate
constant [kel]) were calculated using noncompartmental analysis (Phoe-
nix version 6.3). The area under the concentration-time curve from 0 h to
infinity (AUC0 –) was calculated using the linear up-log down trapezoi-
dal rule. In addition, Cmax and C24 h were directly observed from the data.
Half-life was calculated by ln 2/kel, in which kel was determined by linear
regression of the terminal points of the log-linear plasma concentration-
time curve. V was calculated using the formula V dose/AUC kel, and
CL was calculated as dose/AUC0 –24.
(i) Calculation of isavuconazole concentration in ELF. Concentra-
tions of isavuconazole in BAL fluid from three mice per time point were
determined as described for plasma. Urea in plasma and BAL fluid aspi-
rate was determined utilizing a modified enzymatic assay (QuantiChrom
urea assay kit, DIUR-500; BioAssay Systems) (39, 40). The concentration
of isavuconazole in epithelial lining fluid (ELF) was then determined by
using the ratio of urea concentration in BAL fluid to that in plasma. The
drug concentration in ELF was then estimated, as described previously
(37, 39–44): drug concentrationELF  drug concentrationBAL fluid 
urea
plasma
/ureaBAL fluid.
(ii) Statistical analysis. All data analyses were performed using
GraphPad Prism, version 5.3, for Windows (GraphPad Software, San
Diego, CA). A regression analysis was conducted to determine the
linearity between isavuconazole concentration in blood and that in
ELF. The Cmax data were log10 transformed to approximate a normal
distribution prior to statistical analysis. Mortality data were analyzed
by the log rank test. The survival data were plotted against dose/MIC
and AUC/MIC. The Hill equation with a variable slope was fitted to the
data. The fits were performed for survival data of each strain and all
strains simultaneously. The goodness of fit was checked by R2 and
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visual inspection. Dose/MIC and AUC0 –24/MIC ratios were calculated
by dividing the dose (milligrams per kilogram) or AUC by the MIC.
Dose/MIC and AUC0 –24/MIC ratio data were log10 transformed to
approximate a normal distribution prior to statistical analysis. The
50% effective PK/PD indexes (EI50, EI80, and EI90) best correlating
with efficacy were determined. In addition, the 50% effective doses
(ED50) of isavuconazole best correlating with efficacy were deter-
mined. For comparison between strains, an F test was performed to
define whether ED50 differed among the four groups. Statistical signif-
icance was defined as a P value of 0.05 (two-tailed).
RESULTS
In vitro susceptibility. The characteristics and in vitro suscepti-
bilities of the four A. fumigatus isolates are shown in Table 1. All
isolates grew well after 48 h of incubation at 35 to 37°C. Variable
isavuconazole activity was found in azole-resistant isolates, in
which isavuconazole showed cross-resistance to voriconazole,
but not with itraconazole and posaconazole. In comparison to a
MICEUCAST of 0.5 mg/liter for the wild-type isolate, isavuconazole
showed similar activity against the isolate harboring the G54W
resistance mechanism (MICEUCAST, 0.5 mg/liter) but reduced in
vitro activity against M220I and TR34/L98H isolates, with
MICsEUCAST of 4 and 8 mg/liter, respectively. There was no differ-
ence in the amphotericin B (AmB) and anidulafungin (AFG) ac-
tivity between the isolates.
Pharmacokinetics of isavuconazole. A total of 210 samples
from 210 mice (3 mice per time point, 10 time points, 7 differ-
ent dosages) were analyzed. All 210 mice were alive at the time
of sample collection. The observed plasma concentrations-ver-
sus-time profiles of isavuconazole are shown in Fig. 1. The
corresponding pharmacokinetic parameters are tabulated in
Table 2 for plasma and in Table 3 for epithelial lining fluid
(ELF). The dose-normalized isavuconazole AUC in plasma
ranged from 0.54 to 0.84 mg · h/liter/(mg/kg) for single doses
(dose expressed as the prodrug, concentration expressed as isa-
vuconazole) ranging from 16 mg/kg to 256 mg/kg, was slightly
lower for the 4-mg/kg dose, and could not be reliably deter-
mined for lower doses. The concentrations of isavuconazole in
ELF correlated well with those obtained in plasma but were
lower, including the maximum total drug concentrations
(Cmax) of isavuconazole (Table 3). A significant relationship
between mean isavuconazole concentrations in plasma and
ELF was noted by linear regression analysis (r2  0.86, P 
0.0001) (Fig. 2). The penetration of isavuconazole in ELF based
on total drug was between 35.8 and 72.5% with a mean of
TABLE 1 Disease classification, history of previous azole exposure, underlying azole resistance mechanisms, and in vitro antifungal susceptibilities
of A. fumigatus isolates used in isavuconazole study
Isolate no. Aspergillus diseasea
Prior azole
exposure
Cyp51A
substitution
MIC or MEC (mg/liter) of drug by standard
AmB ITC VRC POS ISA AFG
EUCAST CLSI EUCAST CLSI EUCAST CLSI EUCAST CLSI EUCAST CLSI EUCAST CLSI
AZN8196 Proven IA No None 0.5 0.5 0.125 0.12 0.25 0.25 0.031 0.031 0.5 0.25 0.031 0.031
V 59-73 Clinical, disease
entity unknown
Unknown G54W 0.5 0.5 16 16 0.25 0125 16 16 0.5 0.25 0.031 0.031
V 28-77 Proven IA Yes M220I 0.5 0.5 16 16 0.5 0.25 0.5 0.5 4 2 0.031 0.031
V 52-35 Proven IA No TR34/L98H 0.5 0.5 16 16 4 2 0.5 0.5 8 8 0.031 0.031
a Classification according to EORTC/MSG consensus definitions.
FIG 1 Plasma concentrations of isavuconazole (BAL4815) following oral administration of the prodrug isavuconazonium sulfate (BAL8557) at 0.25-, 1-, 4-, 16-,
64-, 128-, and 256-mg/kg dosages to immunocompetent infected mice. ISA-equivalent doses are 0.12, 0.48, 1.92, 7.68, 30.7, 61.4, and 122.9 mg/kg, respectively.
Each symbol corresponds to the geometric mean and standard deviation of the mean plasma levels for three mice.
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54.1% (Table 3). For the ELF data from the 128-mg/kg dose, kel
(terminal elimination rate constant) could not be determined
with the consequence that the predicted AUC0 – could not be
calculated reliably. Hence, the AUC0 –12s in plasma and ELF
were determined. The variable penetration of isavuconazole
into ELF might be explained due to the difference in lysis of the
cells available in interstitial spaces over the course of infection
that limits passage through alveolar epithelial cells in various
levels; in addition, measurements at the same time in plasma
and a third compartment are liable to significant variation.
Efficacy of isavuconazole. (i) Survival and quantitative PCR
as outcome parameter to monitor therapeutic efficacy of ISA.
Figure 3 shows the survival curves of isavuconazole-treated mice
by prodrug dose. The survival curves for all control groups receiv-
ing saline by oral gavage showed a mortality of 100%. The results
show that for each prodrug dose, survival decreased as the MIC
increased. Similarly, when the prodrug dose was increased, an
improved response was observed. The maximum effect (100%
survival) was reached at a prodose of 64 mg/kg for the wild-type
isolate (MIC, 0.5 mg/liter), 128 mg/kg for the G54W isolate (MIC,
0.5 mg/liter), and 256 mg/kg for the M220I isolate (MIC, 4 mg/
liter). However, the response was lower in the mice infected with
the TR34/L98H isolate (MIC, 8 mg/liter). For the latter isolate, the
maximum dose of isavuconazole (256 mg/kg prodrug) resulted in
27.27% survival in mice.
Isavuconazole therapy significantly reduced kidney Aspergillus
copy numbers at day 3 postinfection. The mean number of ge-
nome copies detected in untreated animals was 3.69  105 in
kidneys (n 3, range 3.5 105 to 3.7 105) at day 3 postin-
fection (Fig. 4; see also Fig. S1 in the supplemental material). Fur-
ther, there was a mean 3- to 4-log10 reduction of A. fumigatus
genome copies in infected animals treated with the highest dosage
of ISA.
(ii) Dose-response analysis. The dose-response curves for the
dosing regimens and control groups of isavuconazole adminis-
tered to the immunocompetent mice are shown in Fig. 5. Isavu-
conazole treatment improved the survival of the mice in a dose-
dependent manner. A dose-response relationship was observed
that depended on the isavuconazole dose and the azole resistance
mechanisms. The dose-response curve for mice infected with the
isolates with higher MICs to isavuconazole (4 mg/liter) was
shifted to the right compared to those infected with isolates with
the susceptible profile for isavuconazole (MIC, 0.5 mg/liter), in-
dicating that higher doses of isavuconazole were required to
achieve similar efficacy.
The Hill-type model with a variable slope fitted the relation-
ship between the dose and 14-day survival well, with R2 values of 1
(wild type), 0.99 (G54W isolate), 0.95 (M220I isolate), and 0.91
for the TR34/L98H isolate. The 50% effective dose (ED50) based on
survival was 24.15 mg/kg prodrug isavuconazonium sulfate
(BAL8557) (95% confidence interval [CI], 23.96 to 24.33 mg/kg)
for the wild type, 28.93 (95% CI, 24.23 to 34.54 mg/kg) for the
G54W isolate, 109 (95% CI, 50.69 to 234.6 mg/kg) for the M220I
TABLE 3 Penetration ratio of isavuconazole (BAL4815) in ELF
compared to plasma based on total druga
ISA dose
(mg/kg)
AUCINF_pred
(h · mg/liter)
AUCINF_pred ELF/
plasma ratio (%)Plasma ELF
64 34.70 25.14 72.45
128 107.41
256 146.68 52.57 35.84
a Because of variability in data and lower limit of quantification, the AUCINF_pred
(predicted area under the plasma concentration-time curve from time zero to infinity)
could not be reliably determined for the 128-mg/kg dose.
FIG 2 Relationship between isavuconazole (BAL4815) concentrations in
plasma and ELF. The line indicates the model fit using linear regression (r2
0.86, P 0.0001).
TABLE 2 Pharmacokinetic parameters of isavuconazole (BAL4815) following oral administration of various dosages administered as prodrug
isavuconazonium sulfate (BAL8557) ranging from 0.25 to 256 mg/kg (ISA-equivalent doses ranging from 0.12 to 122.9 mg/kg)a
Dose group
(mg/kg)
Cmax
(mg/liter)
Clast
(mg/liter) Half-life (h)
AUCINF_pred
(h · mg/liter)
AUCINF_D_pred
(h · mg)/(liters · kg)
CLss_F [liters/
(h · kg)]
Vz_F
(liters/kg)
0.25 0.12 0.12
1 0.11 0.11
4 0.54 0.08 1.12 0.97 0.24 4.09 6.62
16 2.31 0.24 2.49 9.68 0.60 1.68 6.04
64 5.69 0.52 3.00 34.70 0.54 1.87 8.11
128 9.84 2.42 6.06 107. 41 0.84 1.31 11.46
256 25.62 0.15 3.06 146.68 0.57 1.76 7.75
a Abbreviations: Clast, last observed quantifiable concentration; AUCINF_pred, predicted area under the plasma concentration-time curve from time zero to infinity; AUCINF_D_pred,
dose-normalized AUCINF_pred; CLss_F, total systemic clearance; Vz_F, volume of distribution.
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isolate, and 483.8 (95% CI, 103.2 to 2,266 mg/kg) for the TR34/
L98H isolate. Notably, the dose-response curves were significantly
different (P  0.05) between the wild-type A. fumigatus isolate
with an isavuconazole MICEUCAST of 0.5 mg/liter and the azole-
resistant isolates harboring M220I and TR34/L98H substitutions
in the cyp51A gene with isavuconazole MICEUCASTs of 4 and 8
mg/liter, respectively (Table 4).
As a comparison, the ED50 based on survival was 11.6 mg/kg
isavuconazole active moiety (95% confidence interval [CI], 11.5
to 11.7 mg/kg) for the wild type, 13.9 (95% CI, 11.6 to 16.6 mg/kg)
for the G54W isolate, 52.3 (95% CI, 24.3 to 112.6 mg/kg) for the
M220I isolate, and 232.3 (95% CI, 49.52 to 1,089 mg/kg) for the
TR34/L98H isolate.
(iii) Exposure-response analysis. The AUC for each dose (Ta-
ble 2) was used to calculate the AUC0 –24/MIC ratio for each iso-
late, as shown in Fig. 6. The exposure-response relationship has a
sigmoidal shape. Increased isavuconazole exposure was required
to obtain maximum efficacy in mice infected with the M220I
(MIC, 4 mg/liter) and TR34/L98H (MIC, 8 mg/liter) strains com-
pared to those infected with the wild-type and G54W strains
(MIC, 0.5 mg/liter).
The Hill equation with a variable slope fitted the relationship
between the 24-h AUC/MIC ratio and 14-day survival well (R2
0.96), as statistically significant pharmacodynamic indices (PDIs)
for isavuconazole single-agent regimens (P 0.05). The 50% ef-
fective pharmacodynamic index (total AUC0 –24/MICEUCAST) for
isavuconazole was 24.73 (95% confidence interval, 22.50 to
27.18), to be the PD index most closely predictive of efficacy. Us-
ing MICs determined with the CLSI method, the effective
AUC0 –24/MICCLSI ratio for ISA total drug was 50.48 (95% confi-
dence interval, 44.90 to 56.74).
The relationship between the in vivo efficacy and other PDIs,
such as the cumulative percentage of a 24-h period that the drug
concentration exceeded the MIC under steady-state PK condi-
tions and the peak-level Cmax/MIC, was also determined (data not
shown). However, AUC0 –24/MIC appeared to be the most impor-
tant pharmacodynamic index correlating with efficacy.
(iv) Dose fractionation studies. Figure 7 shows the results of
the dose fractionation study. There is no difference between expo-
sure-response relationships of the groups treated with various
dosing intervals.
DISCUSSION
In the present study, the efficacy of isavuconazole was demon-
strated against A. fumigatus wild-type and cyp51A azole-resistant
isolates in an immunocompetent murine model of disseminated
aspergillosis. Efficacy was dependent both on the drug exposure
time and on the isavuconazole MIC of the resistance phenotype of
the isolates. The loss of efficacy was completely or partly compen-
sated by increasing the doses of the prodrug isavuconazonium
sulfate for the azole-resistant strains. However, for mice infected
with the TR34/L98H isolate, which had a high MIC (8 g/ml),
FIG 3 Efficacy of isavuconazole against 4 A. fumigatus isolates. Survival curves are depicted by strain. Therapy by oral gavage once daily was begun 24 h after
infection and continued for 14 days. The isavuconazonium sulfate (BAL8557) doses of 0.25, 1, 4, 16, 64, 128, and 256 mg/kg correspond to ISA-equivalent doses
of 0.12, 0.48, 1.92, 7.68, 30.7, 61.4, and 122.9 mg/kg, respectively. The highest dose (256 mg/kg) was used two times per day, corresponding to 512 mg/kg prodrug
isavuconazonium sulfate (BAL8557)/day, in groups of animals for which 100% efficacy was not achieved with a once-daily dose of 256 mg/kg. Placebo groups
received saline. For all groups, n was 11.
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isavuconazole was not efficacious. Importantly, a maximal effect
of 100% survival was achieved in all strains tested except for the
strain containing the TR34/L98H mutation. This is of significant
importance, since the prevalence of azole resistance in A. fumiga-
tus is increasing, and cross-resistance is a growing concern (12, 21,
32, 45, 46).
A possible limitation of the experimental design used to
explore the PK/PD relationships of isavuconazole in our study
is that the effects were observed in nonneutropenic animals
and the route of infection was dissemination rather than inha-
lation (the normal route of infection). In addition, a significant
difference between tail and intrapulmonary infection is the dif-
ference in inoculum size. A lower inoculum size is needed in
immunosuppressed models. The effects observed could there-
fore be an under- or overestimation of the exposure required.
However, in our previous studies with azoles, we showed that
using survival as a gold standard endpoint in our model pro-
vides useful exposure-response relationships. Studies with
azoles in neutropenic (27, 47, 48) and nonneutropenic (23, 49,
50) models have shown that the exposure–response relation-
ships are of the same order of magnitude; in fact, a slightly
lower drug exposure target may be required in the neutropenic
model. This could possibly be because of the lower inoculum
used in this model.
Isavuconazole is an investigational broad-spectrum triazole
developed for the treatment of severe invasive and life-threatening
fungal diseases (25, 51–54). This compound demonstrated in vitro
activity and in vivo efficacy against a broad range of yeasts and
molds, including Aspergillus spp., Fusarium spp., Candida spp.,
the Mucorales, Cryptococcus spp., and black yeasts and their fila-
mentous relatives (25, 55–63).
In the current study, our model indicated that the primary
driver of efficacy appears to be AUC/MIC. For a survival rate of
50%, the effective AUC0 –24/MICCLSI ratio for isavuconazole
total drug was 50.48 (95% confidence interval, 44.90 to 56.74).
Similarly, the exposure-response relationships of isavucona-
zole have been defined in a recent experimental immunosup-
pressed murine model of invasive pulmonary aspergillosis
(IPA), for which a very strong relationship was observed be-
tween the PD index AUC/MIC ratio and treatment outcome
(27). In that study, 10 A. fumigatus isolates were used, including
four wild-type isolates and six cyp51 mutants. The MICCLSI range
was 0.125 to 8 mg/liter. Following infection, groups of mice were
treated orally with the prodrug BAL8557 at 40 to 640 mg/kg/12 h
FIG 4 Efficacy of isavuconazole against 4 A. fumigatus isolates expressed as A. fumigatus DNA load (copies/nanogram of DNA) in kidneys at 72 h postchallenge.
For all groups, n was 3. Doses were administered as the prodrug isavuconazonium sulfate (BAL8557). The highest dose (256 mg/kg) was used two times per day,
corresponding to 512 mg/kg prodrug isavuconazonium sulfate (BAL8557)/day, in groups of animals for which 100% efficacy was not achieved with a once daily
dose of 256 mg/kg.
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for 7 days. A dose-response relationship was observed for each
isolate, with higher doses of isavuconazole achieving a larger mi-
crobiologic effect. The static-dose range was 65 to 617 mg/kg/12 h,
for which the median total- and free-drug 24-h AUC/MIC ratio
PD targets for net stasis were 503 and 5, respectively. The 1-log10
killing-dose range was 147 to 455 mg/kg/12 h, and the corre-
sponding median free-drug AUC/MIC ratio was 11.1 (27). Since
the AUC of isavuconazole given 200 mg once daily (q.d.) was
reported as approximately 90 mg · h/liter in healthy subjects ap-
proaching steady state (64), we therefore conclude that the A.
fumigatus strains with MICs of 0.5 mg/liter would be covered, and
attainment is most likely reached for strains with MICs of up to 2
or potentially 4 mg/liter.
The efficacy of isavuconazole has also been investigated in an
immunosuppressed murine model of disseminated Aspergillus
flavus infection (65). Isavuconazole demonstrated impressive an-
tifungal activity against A. flavus infection, leading to prolonged
survival, equivalent to similar doses of itraconazole and voricona-
zole and superior to either drug administered at 10 mg/kg/dose.
The excellent efficacy of isavuconazole occurred despite much
lower exposure as demonstrated by 4-fold-lower AUCs. Isavu-
conazole was at least as effective as itraconazole or voriconazole at
reducing organ burden and was able to clear all burden in 33 to
83% of mice treated with15 mg/kg/dose (65).
Three previous studies have examined drug exposure and the
efficacy of isavuconazole in a murine model of invasive candidiasis
(48, 66–68) and showed a very strong relationship between the PD
index AUC/MIC ratio and treatment outcome. One study inves-
tigated the efficacy of isavuconazole using a neutropenic mouse
model of disseminated C. krusei and Candida tropicalis infections.
Isavuconazole was as effective as voriconazole and much more
effective than fluconazole at reducing brain burden. All doses of
isavuconazole (6, 15, 30, 60, 90, 120, or 150 mg/kg equivalent
active compound) reduced brain burden (P  0.05) in the C.
krusei model and kidney burden in the C. tropicalis model (48).
Another study investigated the PK/PD properties of isavuconazole
in a neutropenic murine model of invasive candidiasis (IC)
against clinical isolates of Candida species, including Candida al-
bicans, Candida glabrata, and C. tropicalis, with both a 24-h and a
96-h treatment duration (48). This study has shown that the phar-
macodynamic index most closely correlated with efficacy is the
ratio of the 24-h area under the concentration-time curve (AUC)
to the MIC, and a target 24-h free-drug AUC/MIC ratio near 25
was associated with 50% of maximal microbiologic efficacy (48).
FIG 5 Fourteen-day survival as a function of prodrug isavuconazonium sulfate (BAL8557) dose against 4 A. fumigatus isolates. Shown are data for the isolate
without substitution in the Cyp51A gene (AZN8196; isavuconazole [ISA] MIC, 0.5 mg/liter) and for the G54W (isolate V 59-73; ISA MIC, 0.5 mg/liter) and
M220I (isolate V 28-77; ISA MIC, 4 mg/liter) isolates. MICs are according to EUCAST methodology. The curves indicate fits with the Hill equation for each
isolate.
TABLE 4 Comparison of efficacies of isavuconazole among four A. fumigatus isolates based on ED50
A. fumigatus strain
ISA MIC
(mg/liter)
ISA ED50
(mg/kg)
Comparison with wild type
P value F test (dfn, dfd)
a Difference
Wild type 0.5 24.15
G54W strain 0.5 28.93 0.16 2.88 (1, 4) Nonsignificant
M220I strain 4 109 0.0001 89.89 (1, 7) Significant
TR34/L98H strain 8 438.8 0.002 47.33 (1, 7) Significant
a dfn, degrees of freedom numerator; dfd, degrees of freedom denominator.
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Similarly, using a nonneutropenic murine model of disseminated
Candida albicans infection, it has been shown that the pharmaco-
dynamic driver most likely to predict the outcome of itraconazole
treatment is the AUC/MIC ratio (68).
In addition, in a neutropenic mouse model of intratracheal
infection, Luo et al. investigated the efficacy of isavuconazole
against a brain isolate of Rhizopus delemar (isavuconazole MIC100
and minimum fungicidal concentration [MFC] values of 0.25g/
ml) (69). Isavuconazole was effective against isolates with MIC
and MFC values ranging between 0.125 and 1.00 g/ml. A high
dose of isavuconazole (215 mg/kg of isavuconazonium sulfate
three times daily [t.i.d.]) prolonged the survival time and lowered
the tissue fungal burden of cyclophosphamide-cortisone acetate-
treated mice. In addition, isavuconazole was as effective as a high-
dose liposomal amphotericin B (15 mg/kg, given once daily
through tail vein injection) treatment (69).
In the present study, we also found that the dosing frequency
did not have an impact on survival. Given the half-life of the drug
in mice, which is much shorter than that in humans, a once-daily
dose should therefore suffice and be adequate to treat infections in
humans. Of note, in clinical studies to date, positive efficacy and
safety data have been reported in patients with invasive aspergil-
FIG 6 Percentage of survival as a function of the prodrug isavuconazonium sulfate (BAL8557) AUC0 –24/MIC ratio against 4 A. fumigatus isolates (MIC in
milligrams per liter according to EUCAST methodology). The curve is the model fit with the Hill equation for each data set. MIC values are in milligrams per liter.
FIG 7 Impact of dose fractionation on the in vivo efficacy of prodrug isavuconazonium sulfate (BAL8557) against wild-type A. fumigatus (MIC, 0.5 mg/liter).
Groups of 11 mice were treated q24 (once daily), q12 (fractionated into two doses), and q8 (fractionated into three doses) with the prodrug isavuconazonium
sulfate (BAL8557) administered orally for 14 days. The curve is the model fit with the Hill equation for each data set. The dashed line is the curve fit for all data
sets combined. There was no significant difference in exposure-response relationships among dosing q8, q12, or q24.
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losis (26). Isavuconazole achieved predictable drug levels support-
ing reliable dosing and a switch from once-daily intravenous to
oral administration (26, 70, 71). In addition, no significant food
effect has been found with oral administration of isavuconazole
(72), which in contrast is a potential advantage of isavuconazole
over the oral solution of posaconazole.
In conclusion, our data are an additional promising support
for isavuconazole in the treatment of IA. As with the other azole
antifungal drugs, the efficacy of isavuconazole treatment in A.
fumigatus relies both on drug exposure and on the antifungal sus-
ceptibility of the etiological agent. Therefore, the quantitative re-
lationship between exposure and effect (AUC0 –24/MIC) can be
used to optimize the treatment of human infections by A. fumiga-
tus, including strains with decreased susceptibility.
ACKNOWLEDGMENTS
W.J.G.M. has no conflicts of interest. S.S. has received travel grants from
Astellas Pharma B.V. and Gilead Sciences. R.J.M.B., J.F.M., J.W.M., and
P.E.V. have served as consultants to and have received research grants
from Astellas, Basilea, Gilead Sciences, Merck, and Pfizer.
This research was supported by a collaborative research grant from
Astellas Pharma.
REFERENCES
1. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans
WE, Van Wijngaerden E. 2004. Invasive aspergillosis in critically ill pa-
tients without malignancy. Am J Respir Crit Care Med 170:621– 625. http:
//dx.doi.org/10.1164/rccm.200401-093OC.
2. Denning DW. 1996. Therapeutic outcome in invasive aspergillosis. Clin
Infect Dis 23:608 – 615. http://dx.doi.org/10.1093/clinids/23.3.608.
3. Marr KA, Patterson T, Denning D. 2002. Aspergillosis. Pathogenesis,
clinical manifestations, and therapy. Infect Dis Clin North Am 16:875–
894. http://dx.doi.org/10.1016/S0891-5520(02)00035-1.
4. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E,
Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJ, Verweij
PE. 2011. Clinical implications of azole resistance in Aspergillus fumiga-
tus, The Netherlands, 2007–2009. Emerg Infect Dis 17:1846 –1854. http:
//dx.doi.org/10.3201/eid1710.110226.
5. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE,
Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester
R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E,
Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B,
Invasive Fungal Infections Group of the European Organisation for
Research and Treatment of Cancer and the Global Aspergillus Study
Group. 2002. Voriconazole versus amphotericin B for primary therapy of
invasive aspergillosis. N Engl J Med 347:408 – 415. http://dx.doi.org/10
.1056/NEJMoa020191.
6. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP,
Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van
Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of
America. 2008. Treatment of aspergillosis: clinical practice guidelines of
the Infectious Diseases Society of America. Clin Infect Dis 46:327–360.
http://dx.doi.org/10.1086/525258.
7. Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE,
Pajkrt D. 2009. Multiple-azole-resistant Aspergillus fumigatus osteomy-
elitis in a patient with chronic granulomatous disease successfully treated
with long-term oral posaconazole and surgery. Med Mycol 47:217–220.
http://dx.doi.org/10.1080/13693780802545600.
8. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto
AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009.
Frequency and evolution of azole resistance in Aspergillus fumigatus as-
sociated with treatment failure. Emerg Infect Dis 15:1068 –1076. http://dx
.doi.org/10.3201/eid1507.090043.
9. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA,
Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of
azole resistance in Aspergillus fumigatus and spread of a single resistance
mechanism. PLoS Med 5:e219. http://dx.doi.org/10.1371/journal.pmed
.0050219.
10. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE,
Kuijper EJ, Melchers WJ, Verweij PE. 2009. Azole-resistant central ner-
vous system aspergillosis. Clin Infect Dis 48:1111–1113. http://dx.doi.org
/10.1086/597465.
11. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE.
2007. Aspergillosis—and a misleading sensitivity result. Lancet 370:102.
http://dx.doi.org/10.1016/S0140-6736(07)61055-1.
12. Warris A, Weemaes CM, Verweij PE. 2002. Multidrug resistance in
Aspergillus fumigatus. N Engl J Med 347:2173–2174. http://dx.doi.org/10
.1056/NEJM200212263472618.
13. Hamprecht A, Buchheidt D, Vehreschild JJ, Cornely OA, Spiess B,
Plum G, Halbsguth TV, Kutsch N, Stippel D, Kahl P, Persigehl T,
Steinbach A, Bos B, Hallek M, Vehreschild MJ. 2012. Azole-resistant
invasive aspergillosis in a patient with acute myeloid leukaemia in
Germany. Euro Surveill 17:20262. http://www.eurosurveillance.org/View
Article.aspx?ArticleId20262.
14. Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. 2012.
First reported case of azole-resistant Aspergillus fumigatus due to the TR/
L98H mutation in Germany. Antimicrob Agents Chemother 56:6060 –
6061. http://dx.doi.org/10.1128/AAC.01017-12.
15. Mellado E, De La Camara R, Buendia B, Rodriguez-Tudela JL, Cuenca-
Estrella M. 2013. Breakthrough pulmonary Aspergillus fumigatus infec-
tion with multiple triazole resistance in a Spanish patient with chronic
myeloid leukemia. Rev Iberoam Micol 30:64 – 68. http://dx.doi.org/10
.1016/j.riam.2012.09.002.
16. Chowdhary A, Sharma C, Hagen F, Meis JF. 2014. Exploring azole
antifungal drug resistance in Aspergillus fumigatus with special reference
to resistance mechanisms. Future Microbiol 9:697–711. http://dx.doi.org
/10.2217/fmb.14.27.
17. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF.
2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains
carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob
Chemother 67:362–366. http://dx.doi.org/10.1093/jac/dkr443.
18. Chowdhary A, Kathuria S, Xu J, Meis JF. 2013. Emergence of azole-
resistant aspergillus fumigatus strains due to agricultural azole use creates
an increasing threat to human health. PLoS Pathog 9:e1003633. http://dx
.doi.org/10.1371/journal.ppat.1003633.
19. Chowdhary A, Sharma C, van den Boom M, Yntema JB, Hagen F,
Verweij PE, Meis JF. 7 July 2014. Multi-azole-resistant Aspergillus fu-
migatus in the environment in Tanzania. J Antimicrob Chemother http:
//dx.doi.org/10.1093/jac/dku259.
20. Seyedmousavi S, Hashemi SJ, Zibafar E, Zoll J, Hedayati MT, Mouton JW,
Melchers WJ, Verweij PE. 2013. Azole-resistant Aspergillus fumigatus, Iran.
Emerg Infect Dis 19:832–834. http://dx.doi.org/10.3201/eid1905.130075.
21. Denning DW, Perlin DS. 2011. Azole resistance in Aspergillus: a growing
public health menace. Future Microbiol 6:1229 –1232. http://dx.doi.org
/10.2217/fmb.11.118.
22. Seyedmousavi S, Meletiadis J, Melchers WJ, Rijs AJ, Mouton JW,
Verweij PE. 2013. In vitro interaction of voriconazole and anidulafungin
against triazole-resistant Aspergillus fumigatus. Antimicrob Agents Che-
mother 57:796 – 803. http://dx.doi.org/10.1128/AAC.00980-12.
23. Seyedmousavi S, Bruggemann RJ, Melchers WJ, Rijs AJ, Verweij PE,
Mouton JW. 2013. Efficacy and pharmacodynamics of voriconazole com-
bined with anidulafungin in azole-resistant invasive aspergillosis. J Anti-
microb Chemother 68:385–393. http://dx.doi.org/10.1093/jac/dks402.
24. Lepak AJ, Marchillo K, VanHecker J, Andes DR. 2013. Impact of in vivo
triazole and echinocandin combination therapy for invasive pulmonary
aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimi-
crob Agents Chemother 57:5438 –5447. http://dx.doi.org/10.1128/AAC
.00833-13.
25. Seyedmousavi S, Verweij PE, Mouton JW. 2015. Isavuconazole, a broad-
spectrum triazole for the treatment of systemic fungal diseases. Expert Rev
Anti Infect Ther 13:9 –27. http://dx.doi.org/10.1586/14787210.2015
.990382.
26. Maertens J, Patterson T, Rahav G, Kontoyiannis D, Marr K, Maher R,
Lee M, Zeiher B, Ullmann A. 2013. A phase 3 randomised, double-
blinded trial evaluating isavuconazole vs. voriconazole for the primary
treatment of invasive fungal disease caused by Aspergillus spp. or other
filamentous fungi (SECURE), p O230a. 23rd Eur Congr Clin Microbiol
Infect Dis (ECCMID), Barcelona, Spain.
27. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. 2013. Isavuconazole
(BAL4815) pharmacodynamic target determination in an in vivo murine
model of invasive pulmonary aspergillosis against wild-type and cyp51
Seyedmousavi et al.
2864 aac.asm.org May 2015 Volume 59 Number 5Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother
57:6284 – 6289. http://dx.doi.org/10.1128/AAC.01355-13.
28. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra
T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW,
Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R,
Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC,
Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC,
Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization
for Research and Treatment of Cancer/Invasive Fungal Infections Co-
operative Group, National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised
definitions of invasive fungal disease from the European Organization for
Research and Treatment of Cancer/Invasive Fungal Infections Coopera-
tive Group and the National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis
46:1813–1821. http://dx.doi.org/10.1086/588660.
29. de Valk HA, Meis JF, Curfs IM, Muehlethaler K, Mouton JW, Klaassen
CH. 2005. Use of a novel panel of nine short tandem repeats for exact and
high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin
Microbiol 43:4112– 4120. http://dx.doi.org/10.1128/JCM.43.8.4112-4120
.2005.
30. Rodriguez-Tudela JL, Arendrup MC, Arikan S, Barchiesi F, Bille J,
Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Don-
nelly JP, Fegeler W, Lass-Flörl C, Moore C, Richardson M, Gaustad P,
Schmalreck A, Velegraki A, Verweij P. 2008. EUCAST definitive docu-
ment E.DEF 9.1: method for the determination of broth dilution mini-
mum inhibitory concentrations of antifungal agents for conidia forming
moulds. Subcommittee on Antifungal Susceptibility Testing (AFST) of the
ESCMID European Committee for Antimicrobial Susceptibility Testing
(EUCAST). http://www.eucast.org/.
31. CLSI. 2008. Reference method for broth dilution antifungal susceptibility
testing of filamentous fungi; approved standard—2nd ed. CLSI document
M38-A2, vol 28, no 16. Clinical and Laboratory Standards Institute,
Wayne, PA.
32. Verweij PE, Howard SJ, Melchers WJ, Denning DW. 2009. Azole-
resistance in Aspergillus: proposed nomenclature and breakpoints. Drug
Resist Updat 12:141–147. http://dx.doi.org/10.1016/j.drup.2009.09.002.
33. Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE. 2013. Phar-
macodynamics and dose-response relationships of liposomal amphoteri-
cin B against different azole-resistant Aspergillus fumigatus isolates in a
murine model of disseminated aspergillosis. Antimicrob Agents Che-
mother 57:1866 –1871. http://dx.doi.org/10.1128/AAC.02226-12.
34. Seyedmousavi S, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton
JW. 2013. Pharmacodynamics of anidulafungin against clinical Aspergil-
lus fumigatus isolates in a nonneutropenic murine model of disseminated
aspergillosis. Antimicrob Agents Chemother 57:303–308. http://dx.doi
.org/10.1128/AAC.01430-12.
35. Seyedmousavi S, Melchers WJ, Verweij PE, Mouton JW. 2011. Assess-
ment of efficacy of antifungals in experimental models of invasive asper-
gillosis in an era of emerging resistance: the value of real-time quantitative
PCR. Curr Opin Pharmacol 11:486 – 493. http://dx.doi.org/10.1016/j
.coph.2011.08.001.
36. Seyedmousavi S, Melchers WJG, Bakkers J, Verweij PE, Mouton JW.
2012. Targeting 28S rDNA-gene of Aspergillus fumigatus for pharmaco-
kinetics and pharmacodynamics (PK/PD) studies of voriconazole in a
non-neutropenic murine model of invasive aspergillosis. Mycoses 55:125–
126.
37. Seyedmousavi S, Brüggemann RJ, Melchers WJG, Verweij PE, Mouton
JW. 2014. Intrapulmonary posaconazole penetration at the infection site
in an immunosuppressed murine model of invasive pulmonary aspergil-
losis receiving oral prophylactic regimens. Antimicrob Agents Chemother
58:2964 –2967. http://dx.doi.org/10.1128/AAC.00053-14.
38. Wissen CP, Burger DM, Verweij PE, Aarnoutse RE, Bruggemann RJ.
2012. Simultaneous determination of the azoles voriconazole, po-
saconazole, isavuconazole, itraconazole and its metabolite hydroxy-
itraconazole in human plasma by reversed phase ultra-performance
liquid chromatography with ultraviolet detection. J Chromatogr B
Analyt Technol Biomed Life Sci 887-888:79 – 84. http://dx.doi.org/10
.1016/j.jchromb.2012.01.015.
39. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration
ratios measured in epithelial lining fluid. Antimicrob Agents Chemother
52:24 –36. http://dx.doi.org/10.1128/AAC.00133-06.
40. Rodvold KA, George JM, Yoo L. 2011. Penetration of anti-infective
agents into pulmonary epithelial lining fluid: focus on antibacterial agents.
Clin Pharmacokinet 50:637– 664. http://dx.doi.org/10.2165/11594090
-000000000-00000.
41. Summer R, Kotton DN, Sun X, Ma B, Fitzsimmons K, Fine A. 2003.
Side population cells and Bcrp1 expression in lung. Am J Physiol Lung Cell
Mol Physiol 285:L97–L104. http://dx.doi.org/10.1152/ajplung.00009
.2003.
42. Rennard SI, Basset G, Lecossier D, O’Donnell KM, Pinkston P, Martin
PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid
recovered by lavage using urea as marker of dilution. J Appl Physiol 60:
532–538.
43. Chinard FP. 1992. Quantitative assessment of epithelial lining fluid in the
lung. Am J Physiol 263:L617–L618.
44. VonWichert P, Joseph K, Muller B, Franck WM. 1993. Bronchoalveolar
lavage. Quantitation of intraalveolar fluid? Am Rev Respir Dis 147:148 –
152. http://dx.doi.org/10.1164/ajrccm/147.1.148.
45. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ,
Diekema DJ. 2008. In vitro survey of triazole cross-resistance among
more than 700 clinical isolates of Aspergillus species. J Clin Microbiol
46:2568 –2572. http://dx.doi.org/10.1128/JCM.00535-08.
46. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS,
Denning DW. 2006. Multi-azole resistance in Aspergillus fumigatus. Int J
Antimicrob Agents 28:450 – 453. http://dx.doi.org/10.1016/j.ijantimicag
.2006.08.017.
47. Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J,
Majithiya JB, Warn PA, Hope WW. 2011. Pharmacokinetics and phar-
macodynamics of posaconazole for invasive pulmonary aspergillosis: clin-
ical implications for antifungal therapy. J Infect Dis 203:1324 –1332. http:
//dx.doi.org/10.1093/infdis/jir023.
48. Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. 2013. Isavu-
conazole pharmacodynamic target determination for Candida species in an in
vivo murine disseminated candidiasis model. Antimicrob Agents Chemother
57:5642–5648. http://dx.doi.org/10.1128/AAC.01354-13.
49. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW.
2010. Impact of cyp51A mutations on the pharmacokinetic and pharma-
codynamic properties of voriconazole in a murine model of disseminated
aspergillosis. Antimicrob Agents Chemother 54:4758 – 4764. http://dx.doi
.org/10.1128/AAC.00606-10.
50. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE.
2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus
isolates with mutations in the cyp51A gene. Antimicrob Agents Che-
mother 54:860 – 865. http://dx.doi.org/10.1128/AAC.00931-09.
51. Pasqualotto AC, Denning DW. 2008. New and emerging treatments for
fungal infections. J Antimicrob Chemother 61(Suppl 1):i19 –i30. http://dx
.doi.org/10.1093/jac/dkm428.
52. Thompson GR, III, Wiederhold NP. 2010. Isavuconazole: a comprehen-
sive review of spectrum of activity of a new triazole. Mycopathologia 170:
291–313. http://dx.doi.org/10.1007/s11046-010-9324-3.
53. Falci DR, Pasqualotto AC. 2013. Profile of isavuconazole and its potential
in the treatment of severe invasive fungal infections. Infect Drug Resist
6:163–174. http://dx.doi.org/10.2147/IDR.S51340.
54. Livermore J, Hope W. 2012. Evaluation of the pharmacokinetics and
clinical utility of isavuconazole for treatment of invasive fungal infections.
Expert Opin Drug Metab Toxicol 8:759 –765. http://dx.doi.org/10.1517
/17425255.2012.683859.
55. Martin de la Escalera C, Aller AI, Lopez-Oviedo E, Romero A, Martos
AI, Canton E, Peman J, Garcia Martos P, Martin-Mazuelos E. 2008.
Activity of BAL 4815 against filamentous fungi. J Antimicrob Chemother
61:1083–1086. http://dx.doi.org/10.1093/jac/dkn076.
56. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF.
2011. In vitro activity of isavuconazole against 208 Aspergillus flavus iso-
lates in comparison with 7 other antifungal agents: assessment according
to the methodology of the European Committee on Antimicrobial Sus-
ceptibility Testing. Diagn Microbiol Infect Dis 71:370 –377. http://dx.doi
.org/10.1016/j.diagmicrobio.2011.08.006.
57. Shivaprakash MR, Geertsen E, Chakrabarti A, Mouton JW, Meis JF.
2011. In vitro susceptibility of 188 clinical and environmental isolates of
Aspergillus flavus for the new triazole isavuconazole and seven other an-
tifungal drugs. Mycoses 54:e583– e589. http://dx.doi.org/10.1111/j.1439
-0507.2010.01996.x.
58. Perkhofer S, Lechner V, Lass-Florl C, European Committee on Anti-
microbial Susceptibility Testing. 2009. In vitro activity of isavuconazole
against Aspergillus species and zygomycetes according to the methodol-
Isavuconazole for Treatment of Invasive Aspergillosis
May 2015 Volume 59 Number 5 aac.asm.org 2865Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
ogy of the European Committee on Antimicrobial Susceptibility Testing.
Antimicrob Agents Chemother 53:1645–1647. http://dx.doi.org/10.1128
/AAC.01530-08.
59. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. 2008. In vitro
antifungal activities of isavuconazole (BAL4815), voriconazole, and flu-
conazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fus-
arium, and Scedosporium species. Antimicrob Agents Chemother 52:
1396 –1400. http://dx.doi.org/10.1128/AAC.01512-07.
60. Warn PA, Sharp A, Denning DW. 2006. In vitro activity of a new triazole
BAL4815, the active component of BAL8557 (the water-soluble prodrug),
against Aspergillus spp. J Antimicrob Chemother 57:135–138. http://dx
.doi.org/10.1093/jac/dki399.
61. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Florl C, Martin-
Mazuelos E, Meis J, Pelaez T, Pfaller MA, Turnidge J. 2013. Multicenter
study of isavuconazole MIC distributions and epidemiological cutoff val-
ues for Aspergillus spp. for the CLSI M38-A2 broth microdilution
method. Antimicrob Agents Chemother 57:3823–3828. http://dx.doi.org
/10.1128/AAC.00636-13.
62. Gregson L, Goodwin J, Johnson A, McEntee L, Moore CB, Richardson
M, Hope WW, Howard SJ. 2013. In vitro susceptibility of Aspergillus
fumigatus to isavuconazole: correlation with itraconazole, voriconazole,
and posaconazole. Antimicrob Agents Chemother 57:5778 –5780. http:
//dx.doi.org/10.1128/AAC.01141-13.
63. Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, Fernandez CM,
Boekhout T, Meis JF. 2008. In vitro activity of the new azole isavucona-
zole (BAL4815) compared with six other antifungal agents against 162
Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Che-
mother 52:1580 –1582. http://dx.doi.org/10.1128/AAC.01384-07.
64. Desai A, Zadeikis N, Pearlman H, Kowalski D, Townsend R. 2012.
Effect of multiple doses of isavuconazole on the pharmacokinetics of
CYP3A4 substrate midazolam in healthy volunteers, p M-1936. Abstr
52nd Intersci Conf Antimicrob Agents Chemother (ICAAC), San Fran-
cisco, CA.
65. Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A,
Heep M, Denning DW. 2006. Comparative in vivo activity of BAL4815,
the active component of the prodrug BAL8557, in a neutropenic murine
model of disseminated Aspergillus flavus. J Antimicrob Chemother 58:
1198 –1207. http://dx.doi.org/10.1093/jac/dkl396.
66. Warn PA, Sharp A, Parmar A,Majithiya J, Denning DW,HopeWW. 2009.
Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole:
mathematical modeling, importance of tissue concentrations, and impact of
immune status on antifungal effect. Antimicrob Agents Chemother 53:3453–
3461. http://dx.doi.org/10.1128/AAC.01601-08.
67. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. 2009. Efficacy
of isavuconazole, voriconazole and fluconazole in temporarily neutro-
penic murine models of disseminated Candida tropicalis and Candida
krusei. J Antimicrob Chemother 63:161–166. http://dx.doi.org/10.1093
/jac/dkn431.
68. Te Dorsthorst DT, Verweij PE, Meis JF, Mouton JW. 2004. Pharmaco-
dynamics of BAL4815 a new azole antifungal in a mouse model of systemic
infection, p A-1874. 14th Eur Congr Clin Microbiol Infect Dis (ESCMID),
Prague, Czech Republic.
69. Luo G, Gebremariam T, Lee H, Edwards JE, Jr, Kovanda L, Ibrahim AS.
2014. Isavuconazole therapy protects immunosuppressed mice from mu-
cormycosis. Antimicrob Agents Chemother 58:2450 –2453. http://dx.doi
.org/10.1128/AAC.02301-13.
70. Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J,
Weidekamm E, Brown T, Roehrle M. 2006. Multiple-dose pharmacoki-
netics and safety of the new antifungal triazole BAL4815 after intravenous
infusion and oral administration of its prodrug, BAL8557, in healthy vol-
unteers. Antimicrob Agents Chemother 50:286 –293. http://dx.doi.org/10
.1128/AAC.50.1.286-293.2006.
71. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E,
Brown T, Roehrle M, Beglinger C. 2006. Single-ascending-dose phar-
macokinetics and safety of the novel broad-spectrum antifungal triazole
BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and
oral administrations (100, 200, and 400 milligrams) of its prodrug,
BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50:279 –
285. http://dx.doi.org/10.1128/AAC.50.1.279-285.2006.
72. Schmitt-Hoffman A, Roos B, Roehrle M, Spickermann J, Schoetzau A,
Simmen U, Heep M. 2008. No relevant food effect in man on isavucona-
zole oral pharmacokinetics preliminary data. Abstr 48th Intersci Conf
Antimicrob Agents Chemother (ICAAC)-Infect Dis Soc Am (IDSA) 46th
Annu Meet, Washington, DC.
Seyedmousavi et al.
2866 aac.asm.org May 2015 Volume 59 Number 5Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
